Parvin alpha 抗体 (N-Term)
Quick Overview for Parvin alpha 抗体 (N-Term) (ABIN325027)
抗原
See all Parvin alpha (PARVA) 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- N-Term
- 
                                            特异性
- Detects endogenous levels of total -parvin protein.
- 
                                            纯化方法
- Immunoaffinity purified
- 
                                            免疫原
- 
                        Synthetic peptide (KLH-coupled) corresponding to residues near the amino terminus of human -parvin.
 Type of Immunogen: Synthetic peptide
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- 
                        Approved: WB (1:1000)
 Usage: Suitable for use in Western Blot. Western Blot: 1:1000.
- 
                                            说明
- 
                        Target Species of Antibody: Human 
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- Lot specific
- 
                                            缓冲液
- 10 mM sodium HEPES, pH 7.5, 150 mM sodium chloride, 100 g/mL BSA, 50 % glycerol.
 
- 
                                            
- 
    - Parvin alpha (PARVA) (Parvin, alpha (PARVA))
- 
                                            别名
- PARVA
- 
                                            背景
- 
                        Name/Gene ID: PARVA
 Synonyms: PARVA, Actopaxin, Alpha-parvin, CH-ILKBP, Parvin, alpha, MXRA2
- 
                                            基因ID
- 55742
- 
                                            UniProt
- Q9NVD7
- 
                                            途径
- Smooth Muscle Cell Migration
 抗原
- 
                    
 
                                     
                                     
                                    